FAM162A Promotes Osteosarcoma Progression Via Activating HIF‐1α to Enhance Glycolysis
Molecular Carcinogenesis · 2026-06 · 65 (6) · 715-727
DOI: 10.1002/mc.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 26.03.2026. Verfasst von Jun Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Osteosarcoma, Glycolysis, Bone Neoplasms. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Key research and development plan of Shaanxi Province.
Abstract (Originalsprache)
Osteosarcoma (OS) [1] is the most prevalent primary bone cancer and is highly prone to both local invasion and metastasis. FAM162A, a protein implicated in cell growth transformation, is recognized as an oncogene in various cancers. Its role in osteosarcoma, however, remains poorly understood. This study investigates the role of FAM162A in the OS development. We identified that FAM162A was observably upregulated in osteosarcoma and inversely correlated with the prognosis of patients using bioinformatics and immunohistochemical analysis. The CCK‐8, colony formation, scratch, and trans‐well migration assays were performed to detect the effects of FAM162A on OS cell proliferation and migration. Then we found FAM162A‐associated pathways in OS using GO and KEGG analyses and verified and used the downstream factor HIF‐1α inhibitor to restore the OS cell proliferation induced by FAM162A overexpression to detect the mechanism of FAM162A in OS. Mechanistically, FAM162A facilitates glycolysis by activating HIF‐1α and subsequently PKM2, a critical glycolytic gene, thereby advancing OS progression. These insights elucidated FAM162A's involvement in OS and its impact on glucose metabolism reprogramming, underscoring its potential as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Emergency Surgery Department, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
- Emergency Surgery Department, Taikang Clinical College of Wuhan University, Taikang Tongji Wuhan Hospital, Wuhan, Hubei, China.
- Department of Pain and Rehabilitation, Wuhan Clinical Research Center for Acupotomy Medicine, Wuhan Third Hospital, Wuhan, Hubei, China.
- Department of Medicine, School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, China.
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Jun Zhang
Förderung
- Key research and development plan of Shaanxi Province
Zitieren
APA
Zhang, J., Liu, Z., Fan, L., Cao, R., Miao, Z., Guo, C., Yu, N., Yu, H., & Dang, X. (2026). FAM162A Promotes Osteosarcoma Progression Via Activating HIF‐1α to Enhance Glycolysis. Molecular Carcinogenesis, 65(6), 715-727. https://doi.org/10.1002/mc.70112
Vancouver
Zhang J, Liu Z, Fan L, Cao R, Miao Z, Guo C, et al. FAM162A Promotes Osteosarcoma Progression Via Activating HIF‐1α to Enhance Glycolysis. Molecular Carcinogenesis. 2026;65(6):715-727. doi:10.1002/mc.70112
BibTeX
@article{Zhang2026,
author = {Zhang, Jun and Liu, Zhigang and Fan, Li and Cao, Rubo and Miao, Zhuang and Guo, Chenxin and Yu, Ningning and Yu, Haotian and Dang, Xiaoqian},
title = {FAM162A Promotes Osteosarcoma Progression Via Activating HIF‐1α to Enhance Glycolysis},
journal = {Molecular Carcinogenesis},
year = {2026},
volume = {65},
number = {6},
pages = {715--727},
doi = {10.1002/mc.70112}
}
EUVIMED